Figure 3.

IL-37 Var2 is unstable and degraded by the proteasome-mediated pathway. HEK293T cells stably expressing IL-37 variants were treated with the protein synthesis inhibitor CHX (100 μg/ml) or the proteasome inhibitor MG132 (10 μm) or both. Cells were collected at different time points, and IL-37 levels were monitored by western blotting. Representative blots are shown, and the dotted-line plots below summarize the data from three experiments. IL-37 variant expression levels were normalized to β-actin. The value at 0 h was set to 1 unit, and other values were calculated relative to this value. The data are presented as the mean±standard error. *P<0.05, **P<0.01, vs 0 h.